Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration

R.W. Essex, V. Nguyen, R. Walton, J.J. Arnold, Ian Mcallister, R.H. Guymer, Nigel Morlet, S. Young, D. Barthelmes, M.C. Gillies

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

© 2016 American Academy of Ophthalmology

Purpose To present the treatment patterns, disease activity, and visual outcomes of eyes in the maintenance phase of a treat-and-extend regimen for neovascular age-related macular degeneration (nAMD). To compare the maintenance phase behavior of eyes with a shorter induction phase (=3 injections) with those requiring a longer induction phase (>3 injections). Design Database observational study. Participants Eyes with nAMD receiving anti-vascular endothelial growth factor (VEGF) treatment using a treat-and-extend protocol. Persistently active eyes were excluded, as were eyes with 0 letters and =15 letters). Results The mean change in visual acuity during the maintenance phase was +1.0 letters at 12 months -0.6 letters at 24 months and -1.5 at 36 months. Median treatment interval increased from 35 days at study entry to 63 days at 12 months and was 60 days at 36 months. 38.5% of eyes remained inactive at all observed visits during the maintenance phase (minimum 1 year follow-up, mean 945 days). The most common treatment interval at first reactivation was 8 weeks. Treatment intervals beyond 12 weeks seemed to be associated with increased risk of disease reactivation, with risk of reactivation reaching 37.4% at treatment intervals of =20 weeks. Eyes with a longer induction phase had worse visual outcomes in the maintenance phase, and earlier and more-frequent disease reactivation,

Original languageEnglish
Pages (from-to)2393-2400
JournalOphthalmology
Volume123
Issue number11
Early online date20 Aug 2016
DOIs
Publication statusPublished - Nov 2016

Fingerprint Dive into the research topics of 'Treatment Patterns and Visual Outcomes during the Maintenance Phase of Treat-and-Extend Therapy for Age-Related Macular Degeneration'. Together they form a unique fingerprint.

Cite this